[18F]DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function.

[1]  D. Standaert,et al.  Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method , 2022, Diagnostics.

[2]  T. Guilarte,et al.  Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization. , 2021, Pharmacology & therapeutics.

[3]  F. Turkheimer,et al.  Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation , 2021, Brain, Behavior, and Immunity.

[4]  F. Turkheimer,et al.  Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  P. Remy,et al.  Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. , 2020, Parkinsonism & related disorders.

[6]  Steven H. Liang,et al.  Recent developments on PET radiotracers for TSPO and their applications in neuroimaging , 2020, Acta pharmaceutica Sinica. B.

[7]  M. Battaglini,et al.  Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis , 2020, The Journal of Nuclear Medicine.

[8]  W. Stummer,et al.  Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Junjie Zhu,et al.  Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice , 2019, Acta pharmaceutica Sinica. B.

[10]  Yiyun Huang,et al.  Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study , 2019, bioRxiv.

[11]  R. Banerjee,et al.  Cytochrome P450 research and The Journal of Biological Chemistry , 2019, The Journal of Biological Chemistry.

[12]  M. Pomper,et al.  Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation , 2018, The Journal of Nuclear Medicine.

[13]  M. Leboyer,et al.  Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study) , 2018, Front. Psychiatry.

[14]  H. Lövheim,et al.  Clinically relevant drug–drug interactions among elderly people with dementia , 2018, European Journal of Clinical Pharmacology.

[15]  Fabian Corlier,et al.  Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease , 2018, Brain : a journal of neurology.

[16]  E. Tajkhorshid,et al.  Drug-Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4. , 2017, Biochemistry.

[17]  K. Ishii,et al.  Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteers , 2017, EJNMMI Research.

[18]  Olivier Colliot,et al.  Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. , 2016, Brain : a journal of neurology.

[19]  Paul D. Martin,et al.  Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies , 2016, Drugs in R&D.

[20]  P. Remy,et al.  Optimized Quantification of Translocator Protein Radioligand 18F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers , 2015, The Journal of Nuclear Medicine.

[21]  M. Guillermier,et al.  [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  M. Mandelkern,et al.  Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers. , 2014, Nuclear medicine and biology.

[23]  Annelaure Damont,et al.  Metabolism and Quantification of [18F]DPA-714, a New TSPO Positron Emission Tomography Radioligand , 2013, Drug Metabolism and Disposition.

[24]  A. Reynolds,et al.  Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. , 2012, Nuclear medicine and biology.

[25]  Myung G. Lee,et al.  Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  F. Dollé,et al.  [18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[27]  S. Meikle,et al.  The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice , 2012, PloS one.

[28]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  J. Hirvonen,et al.  Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Masahiro Fujita,et al.  Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker , 2010, NeuroImage.

[31]  Leah P. Dickstein,et al.  Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, 18F-PBR06, to Image Translocator Protein (18 kDa) , 2010, Journal of Nuclear Medicine.

[32]  Sunhee C. Lee,et al.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain , 2009, Neuropathology and applied neurobiology.

[33]  Annelaure Damont,et al.  Comparative Evaluation of the Translocator Protein Radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a Rat Model of Acute Neuroinflammation , 2009, Journal of Nuclear Medicine.

[34]  Denis Guilloteau,et al.  DPA-714, a New Translocator Protein–Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization , 2008, Journal of Nuclear Medicine.

[35]  Jeih-San Liow,et al.  Radiation Dosimetry and Biodistribution in Monkey and Man of 11C-PBR28: A PET Radioligand to Image Inflammation , 2007, Journal of Nuclear Medicine.

[36]  Koujirou Yamamoto,et al.  Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[37]  J. Herranz,et al.  10-Hydroxycarbazepine Serum Concentration-to-Oxcarbazepine Dose Ratio: Influence of Age and Concomitant Antiepileptic Drugs , 2005, Therapeutic drug monitoring.

[38]  D. Greenblatt,et al.  The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.

[39]  D. Guay.  Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. , 2004, The American journal of geriatric pharmacotherapy.

[40]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[41]  O. Pelkonen,et al.  In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists , 2000, European Journal of Clinical Pharmacology.

[42]  S. Caccia.  Metabolism of the Newer Antidepressants , 1998, Clinical pharmacokinetics.

[43]  O. Inoue,et al.  Synthesis and evaluation of11C-PK 11195 forin vivo study of peripheral-type benzodiazepine receptors using position emission tomography , 1989 .

[44]  G. Small,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors , 2002, Clinical pharmacokinetics.